- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07620808
MTM2MTG Pilot Ancillary Study (MTM2MTG)
1 giugno 2026 aggiornato da: Nour Makarem, PhD, Columbia University
Medically Tailored Groceries for Cardiovascular Health
The investigators will conduct an ancillary study of participants in a completed RCT of medically tailored meals to determine whether transitioning these participants to a medically tailored groceries (MTG) program is a feasible approach to sustain health effects.
Panoramica dello studio
Stato
Iscrizione su invito
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This ancillary study is a single arm, pre-post design among adults with co-existing type 2 diabetes and elevated to high blood pressure who do not currently qualify for medically tailored meals (MTMs) but received them as part of their participation in an 8-month RCT on MTMs and cardiometabolic outcomes.
The purpose of the ancillary study is to determine whether transitioning participants from a MTM to a MTG program (i.e., a hybrid MTM to MTG intervention) is a feasible approach to improve outcomes and sustain health effects.
Participants will receive one box of medically tailored groceries each week for a period of 4 months, with each box supporting preparation of approximately 10 meals per week.
No additional baseline visit will be required, as measurements collected at the 8-month visit in the parent clinical trial will serve as baseline values for the ancillary study.
All participants will have their HbA1c and blood pressure measured and complete questionnaires about their diet quality, health and lifestyle behaviors, and program engagement and implementation at 4 months post receiving their first MTG box.
Tipo di studio
Interventistico
Iscrizione (Stimato)
80
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
New York
-
New York, New York, Stati Uniti, 10032
- Columbia University Mailman School of Public Health
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Descrizione
Inclusion Criteria:
- Type 2 diabetes diagnosis (physician diagnosed or HbA1c greater than or equal to 6.5% or diabetes medication use)
- Hypertension diagnosis (systolic blood pressure greater than or equal to 130 mmHg and/or diastolic blood pressure greater than or equal to 80 mmHg or physician diagnosis or hypertension medication use) or elevated blood pressure (defined as systolic blood pressure greater than or equal to 120 mmHg)
- Participation in parent trial investigating the impact of an 8-month medically-tailored meals (MTMs) intervention on cardiometabolic outcomes among adults with type 2 diabetes and elevated to high blood pressure who do not currently qualify for MTMs.
Exclusion Criteria:
- Cancer diagnosis
- Undergoing cancer treatment
- Non-English or non-Spanish speaking
- Not cognitively able to complete study requirements
- Severe psychiatric disorders
- Inability to provide informed consent
- Health conditions that could prevent safe participation or impact study outcomes (e.g., substance use disorder, dialysis, neurodegenerative conditions)
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Altro: Ancillary Study: Medically Tailored Groceries (MTG) Program
Participants in this ancillary study are adults with type 2 diabetes and elevated to high blood pressure who do not currently qualify for medically tailored meals (MTMs) but received them as part of a RCT for 8 months.
This ancillary study evaluates whether transitioning from MTMs to MTGs is a feasible approach to maintain MTM intervention health effects and could be a better tolerated intervention for participants who are not engaged with the MTM intervention.
Participants will receive one MTG box per week for 4 months, supporting preparation of ~10 heart healthy, diabetes appropriate meals per week.
Outcomes will be assessed at the end of the 4-month MTG intervention period using questionnaires and clinic measurements (blood pressure and HbA1c).
The 8-month primary endpoint visit for the parent RCT will serve as the baseline for this study.
|
God's Love We Deliver's current MTG program (Health Harvest), which consists of weekly home-delivered MTG boxes, recipes and educational materials/webinars developed by Registered Dietitian Nutritionist for a 4-month period.
The participants in the ancillary study will receive 1 MTG box/week which provides food sufficient for approximately 10 meals/week and includes fresh fruits, vegetables, whole grains, and proteins for a period of 4 months.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Diet Quality
Lasso di tempo: Baseline, 4 months
|
The Mediterranean Eating Pattern for Americans (MEPA) scale, which captures adherence to a heart healthy dietary pattern, will be used to assess diet quality.
The MEPA score ranges from 0-16 with higher scores indicating better diet quality.
The change in MEPA scores from baseline to 4 months will be calculated.
|
Baseline, 4 months
|
|
Change in HbA1c
Lasso di tempo: Baseline, 4 months
|
A fast and accurate HbA1c fingerstick test will assess changes in glycemic control from baseline to 4 months.
|
Baseline, 4 months
|
|
Change in systolic blood pressure
Lasso di tempo: Baseline, 4 months
|
The change in office systolic blood pressure (mmHg) from baseline to 4 months will be calculated.
|
Baseline, 4 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in diastolic blood pressure
Lasso di tempo: Baseline, 4 months
|
The change in office diastolic blood pressure (mmHg) from baseline to 4 months will be calculated.
|
Baseline, 4 months
|
|
Acceptability of Implementation
Lasso di tempo: 4 monthd
|
Acceptability will be measured by questionnaire.
Items are adapted from the validated Acceptability of Implementation Measure (AIM) and are rated on a 5-point Likert scale ranging from 1 to 5, with 1 indicating "Completely disagree" and 5 indicating "Completely agree."
Higher scores indicate better intervention acceptability.
The items are analyzed individually and not summed to a total score.
|
4 monthd
|
|
Feasibility of Implementation
Lasso di tempo: 4 months
|
Feasibility will be measured by questionnaire using items adapted from the validated Feasibility of Implementation Measure (FIM) and rated on a 5-point Likert scale ranging from 1 to 5, with 1 indicating "Completely disagree" and 5 indicating "Completely agree."
Higher scores indicate better feasibility.
The items are analyzed individually and not summed to a total score.
|
4 months
|
|
Appropriateness of Implementation
Lasso di tempo: 4 months
|
Appropriateness will be measured by questionnaire.
Items are adapted from the validated Implementation Appropriateness Measure (IAM) and are rated on a 5-point Likert scale ranging from 1 to 5, with 1 indicating "Completely disagree" and 5 indicating "Completely agree."
Higher scores indicate better appropriateness.
The items are analyzed individually and not summed to a total score.
|
4 months
|
|
Satisfaction with Intervention
Lasso di tempo: 4 months
|
Satisfaction with the intervention components will be measured by questionnaire.
Participants will rate their satisfaction with intervention by indicating how likely they are to recommend it to others on a 10-point scale with higher scores indicating greater satisfaction (net promoter score).
They will also be asked to rate the quality of the intervention as poor, fair, good, very good, or excellent.
The items are analyzed individually and not summed to a total score.
|
4 months
|
|
Food Insecurity
Lasso di tempo: Baseline, 4 months
|
The USDA Household Food Security Survey (FSSM-6 item) will be administered at baseline, 3 months, and 8 months.
The scores range from 0-6 such that a score of 0-1 indicates high or marginal food security, 2-4 indicates low food security, and 5-6 indicates very low food security.
Changes in the score from baseline to follow up at 4 months.
|
Baseline, 4 months
|
|
Nutrition Insecurity
Lasso di tempo: Baseline, 4 months
|
The Gretchen Swanson 4-item nutrition screener will be administered at baseline, 4 months (score range: 0-4 with higher scores indicating higher nutrition security).
Changes in the score from baseline to follow up at 4 months will be evaluated.
|
Baseline, 4 months
|
|
Sleep Duration
Lasso di tempo: Baseline, 4 months
|
Sleep duration will be self-reported using the Pittsburgh Sleep Quality Index (PSQI, score range: 0-21).
Changes in self-reported habitual hours of sleep from baseline to follow up at 4 months will be evaluated.
|
Baseline, 4 months
|
|
Pittsburgh Sleep Quality Index
Lasso di tempo: Baseline, 4 months
|
Global sleep quality will be measured using the Pittsburgh Sleep Quality Index (PSQI, score range: 0-21).
Changes in the overall PSQI score (continuous and categorical) and its components from baseline to follow up at 4 months will be evaluated.
|
Baseline, 4 months
|
|
Self-rated health
Lasso di tempo: Baseline, 4 months
|
Participant will rate their health as excellent, very good, good, fair, or poor at baseline,4 months.
Changes in self-rated health from baseline to follow up at 4 months will be computed.
|
Baseline, 4 months
|
|
General Health Status
Lasso di tempo: Baseline, 4 months
|
The EuroQoL 5-Dimension 5-Level (EQ-5D-5L) will be used to measure general health status and quality of life.
This will be captured based on five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, and each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Based on the participant's response for reach dimension they will receive a 1-digit number, and the digits for the five dimensions will be combined into a 5-digit number that describes the patient's health state.
This study will evaluate changes in this measure from baseline to follow up at 4 months.
I
|
Baseline, 4 months
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Investigatori
- Investigatore principale: Nour Makarem, PhD, FAHA, Columbia University
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Stimato)
1 giugno 2026
Completamento primario (Stimato)
1 giugno 2027
Completamento dello studio (Stimato)
1 giugno 2027
Date di iscrizione allo studio
Primo inviato
27 maggio 2026
Primo inviato che soddisfa i criteri di controllo qualità
27 maggio 2026
Primo Inserito (Effettivo)
2 giugno 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
3 giugno 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
1 giugno 2026
Ultimo verificato
1 giugno 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- AAAV0681 - Ancillary Study
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Descrizione del piano IPD
Data may be shared upon request to PI.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Pressione sanguigna
-
Andrew Hantel, MDNon ancora reclutamentoMieloma multiplo | Cancro al seno triplo negativo | Duffy Blood Group, Chemokine Receptor Gene Mutation | Duffy Blood Group, Chemokine Receptor Gene C.-67T>CStati Uniti
-
Zhongnan HospitalReclutamentoMicrotrapianto di UCB (Cord Blood) nel trattamento della leucemia mieloide acuta (AML) di nuova diagnosiCina
-
Hangzhou Agile Groups Network Technology Co., Ltd.CompletatoAnemia | Condizione della pelle | Sindrome da carenza di blind Qi-BLOODCina
Prove cliniche su Medically Tailored Groceries
-
Anne E RayNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Klein Buendel, Inc.; University of North Texas Health Science CenterNon ancora reclutamentoComportamento sessuale | Bere alcolici al collegeStati Uniti